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Introduction
The functional interactions between the immune,
endocrine and nervous systems occur at different
levels, which underline their relevance in controlling
physiological processes. Any disturbances herein may
be potentially involved in certain pathological condi-
tions (1, 2). Studies in animal models have demon-
strated that abnormalities in immune±neuroendocrine
communications may start or contribute to the devel-
opment of chronic autoimmune diseases. By analogy,
similar questions have been raised for humans. Neuro-
endocrine and immune systems share a number of
ligands and related receptors (3). The majority of these
signalling molecules are highly conserved and, via these
products, the systems in many species are able to
establish sophisticated physiological intra- and inter-
system communication circuits (4). The bidirectional
neuroendocrine±immune interactions may constitute
an important homeostatic mechanism (5).
In their physiological environment, immune cells are
exposed to agents such as hormones and neuropeptides.
These cells can produce hormones and neuropeptides
themselves and may express speci®c receptors for
neuroendocrine regulatory peptides as well (6±8). In
addition, lymphoid tissues are directly and extensively
innervated, the nerve ®bres being in direct contact with
lymphocytes or their precursors as well as macro-
phages, performing their neuro-effector functions.
In Table 1 the principal neuropeptides involved in
controlling the immune system are indicated together
with their effects on immune function. The distribution
of neuropeptide receptors in the immune system has
some common characteristics. Their expression pattern
on different types of immune cells is heterogeneous,
suggesting that the signal mediated by these agents can
preferentially target different types of immune
responses. Another important aspect is that the
number or the activity of neuropeptide receptors on
immunocytes may change during the speci®c and
aspeci®c activation of these cells, suggesting that signals
mediated by one of this effectors could be predominantly
perceived by antigen-activated cells (1). This evidence
may partially explain the rather common occurrence of
con¯icting observations that neuroendocrine-mediated
activities exert on immune cells.
Many recent studies have pointed to the presence and
functional roles of somatostatin (SS) and its receptors on
the cells of the immune system (9, 10). SS is a peptide
hormone widely distributed throughout the human
body, involved in regulating neurotransmission in the
brain, as well as secretion processes in the anterior
pituitary gland, the pancreas and the gastrointestinal
tract (11±13). An antiproliferative action of SS has been
observed in many cell types in vitro as well (12). Five
different SS receptor (SST) genes originate multiple SST
subtypes (sst1±5) and, although the genes have a high
degree of sequence homology, they are localized on
different chromosomes, which allows a tissue-speci®c
regulation of their expression and suggests diverse
functions of the receptor subtypes in different organs
(14±17). The ®ve SST subtypes bind native SS with
high af®nity but can be further divided into two
subclasses on their ability to bind structural octapeptide
SS analogues. Three octapeptide SS analogues, octreo-
tide, lanreotide and vapreotide, have already been
introduced into clinical practice (Fig. 1). sst1 and sst4
receptors do not bind these analogues, whereas sst2A,
sst3 and sst5 receptors display a high, low and
moderate af®nity, respectively, towards octapeptide SS
analogues.
Among lymphatic organs, the thymus from different
species, including the human, has been shown to
contain the highest amount of SS (7, 8, 18). Although
experimental models in animals have suggested the
signi®cant participation of different neuropeptides in
the activities of the thymus, the exact role of SS in this
context is still obscure.
SS and SST in the thymus
Structure and function of the human thymus
The thymus is a central lymphoid organ in mammals
and it plays a pivotal role in the control of the immune
system. The presence of the thymus and its functionality
are required for full establishment of immunocompe-
tence. The thymus involutes with constant velocity
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during the ®rst decade of life. Thereafter, the involution
process decreases progressively (19). Connective and
adipose tissues replace most of the thymic tissue,
although some functional tissue remains throughout
life (19, 20).
The thymus is covered by a thin connective tissue
capsule and lobulated by septa originating from it.
Septa, carrying vessels and nervous ®bres, penetrate
from the capsule to the central part of the organ
designing the structure of cortex and medulla. These
two regions can be distinguished because of the different
density of the lymphoid cells. The medulla exhibits small
and medium-sized lymphoid cells, as well as its typical
Hassall's corpuscles. The thymus has four principal cell
types: thymocytes, the so-called `lymphocytes of the
thymus', which are the precursors of peripheral T
lymphocytes; few macrophages and dendritic cells,
which are all cells of bone marrow origin. The fourth
type is a heterogeneous population of specialized thymic
epithelial cells (TEC), which provide a supporting
framework (the stroma) for the parenchyma. TEC,
together with macrophages and dendritic cells drive
the maturation and differentiation of thymocytes into
mature lymphocytes, through cell-to-cell contacts and
via soluble products. Thymic epithelium is a hetero-
geneous tissue, and cells in different locations within
the lobules in¯uence speci®c steps in thymocyte
maturation. At least three phenotypically different
types of epithelial cells are present in the thymus,
cortical TEC, medullary TEC, and subcapsular epithe-
lium. However, it seems that more subsets may be
distinguished and identi®ed on the basis of different
content and type of cytokeratin (21). A schematic
structure of a human thymic lobule is shown in Fig. 2.
In the thymus, the immature T cells proliferate and
differentiate. The positively selected cells migrate to the T-
cell-dependent areas of peripheral lymphoid organs, such
as spleen, lymph nodes and tonsil (22). This process
persists throughout life; however, the number of develop-
ing elements decays with ageing. Together with differ-
entiation, precursors of T cells interact with various
components of the thymic microenvironment (22).
During migration, thymocytes follow a predisposed
direction and are driven from the cortex to the medulla.
In the ®rst step, after a very active proliferative phase,
thymocytes with high avidity are negatively selected and
deleted by apoptosis, while those with intermediate
avidity for recognition of major histocompatibility com-
plex-self peptide are rescued and positively selected.
Positive selection seems mainly mediated by TEC, whereas
bone marrow-derived cells (macrophages and dendritic
cells) essentially exert negative selection (22, 23).
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Table 1 Effects of neuropeptides on immune functions.
Main effect
Immunoglobulin Cytokine Cell-mediated In¯ammation
Neuropeptide production secretion immunity
Adrenocorticotrophic hormone # "# # ±
Corticotrophin-releasing hormone # "# # #
Vasopressin ± ± ± "
b-Endorphin " "# " "
a-Melanocyte-stimulating hormone ± # # #
Enkephalin " " " "
Calcitonin gene-related peptide ± # ± #
Nerve growth factor " ± ± "#
Somatostatin # "# ± "#
Substance P "# " ± "
Vasoactive intestinal peptide "# # "# ±
", increased response/activity; #, decreased response/activity; "#, variable response.
Figure 1 Amino acid sequences of native SS-14 and synthetic
stable octapeptide analogues octreotide (SMS 201±995), lanreo-
tide (BIM23014) and vapreotide (RC-160). The darker shading
indicates the amino acids essential for binding with the receptor.
Neuroendocrine control of the human thymus
Pituitary hormones, thyroid hormones, steroids and
neuropeptides can indirectly and directly modulate
thymocyte development, conveying positive and nega-
tive signals for thymocyte proliferation (24). Moreover,
evidence that cytokine production by thymocytes may
be under neuroendocrine control has been provided
(25±27). The intrathymic production of many of these
factors, as well as the expression of their speci®c
receptors, has been characterized during recent years
(Table 2). Thus, in addition to the classical endocrine
pathways, paracrine and autocrine mechanisms are
implicated in the in¯uence of hormones and neuropep-
tides on the thymus (24). This strongly suggests that
normal circulating levels as well as controlled local
production of these factors are necessary to preserve the
homeostasis and the various biological functions related
to both the microenvironmental and lymphoid cells of
this important organ. Recently, our research has been
focused on SS and its receptors as clinical consequences
of their local activity in the cross-talk between speci®c
subsets of thymic cells in both normal and pathological
events in the human thymus.
Distribution and signi®cance of SS and SST in
the human thymus
SS-binding sites have been demonstrated in various
human lymphoid tissues (28, 29). Binding studies and
reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis have been used to characterize SS and
SST subtype expression in the normal human thymus.
SS and three SST subtypes, sst1, sst2A and sst3 have been
found in thymic tissue (30). The expression of these
different subtypes appeared heterogeneous within the
tissue and on different cell subsets. A selective expres-
sion of sst1 and sst2A has been found on cultured TEC, in
line with the evidence of [125I-Tyr3]-octreotide binding
in the thymic medulla, where TEC is the prevalent cell
type. TEC were also found to be a potential source of
SS production within the thymus, since SS mRNA has
been detected in these cells (30). Conversely, SS mRNA
was undetectable in thymocytes and the distribution of
SST subtypes on this heterogeneous cell population
appears to be rather more complex (31). In fact, in
freshly isolated thymocytes, sst2A and sst3 mRNA
expression has been detected while, in long-term
cultured thymocytes, no mRNA encoding for SST
subtypes was detectable, suggesting a relatively rapid
down-regulation of SSTs on thymocytes during culture
(D Ferone, PM van Hagen, SWJ Lamberts & LJ Ho¯and,
unpublished observations). Moreover, thymocytes at
different levels of maturation seemed to express variable
amounts of sst2A and sst3 mRNA compared with those
in the whole population. In general, the number of SS-
binding sites on thymocytes is low (32). This is in
agreement with the presence of a low number of SS-
binding sites on circulating human T lymphocytes (33),
which derive from thymocytes. Finally, on macrophages,
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Figure 2 Schematic reproduction of a thymic lobule. Thymocytes during maturation are driven from the cortex to the medulla having, in the
meantime, many contacts with a heterogeneous cellular network, including TEC, dendritic cells and macrophages. TEC represent a
heterogeneous group with a distinct subset of cells in the cortex and in the medulla. Hassall's corpuscles probably represent sites of cell
destruction and are typically localized in the medulla.
the third thymic cell component examined, the presence
of only sst2A mRNA was detected (D Ferone, PM van
Hagen, SWJ Lamberts & LJ Ho¯and, unpublished
observations). This ®nding is in agreement with
previous reports showing the selective expression of
this SST subtype on human macrophages and mono-
cytes (34, 35, 69). The presence of functional SST
subtypes on TEC and thymocytes has been demon-
strated by in vitro studies on isolated cell cultures using
SS and the SS analogue octreotide (30, 32). In our
experience, both these compounds inhibited the basal
and growth factor-stimulated TEC proliferation (30).
However, preliminary data showed a dose-dependent
inhibitory effect of SS on resting human thymocytes as
well (D Ferone, PM van Hagen, SWJ Lamberts & LJ
Ho¯and, unpublished observations).
An additional important piece of evidence is that the
expression pattern of SST subtypes in the thymus seems
to show a species-speci®c distribution. In fact, there are
substantial differences between man and the two more
extensively studied animal models, i.e. the rat and the
mouse (36±39). These differences make both these two
models rather unsuitable for studying the effects of SS
on human thymic cells. Also the local production of SS
seems to have a different source in mouse and human.
In fact, SS mRNA has been found in human TEC, but
not in thymocytes or monocyte/macrophage lineage
cells, whereas in mouse the peptide is mainly present in
macrophages (30, 40).
Taking into consideration the peculiar human thymic
microenvironment, its architecture and the speci®c
pattern of SST distribution, the existence of specialized
areas where SS and its receptors might exert differential
activities may be hypothesized. On microenvironmental
cells, sst2A seems to be the receptor predominantly
expressed and an autocrine or paracrine activity of SS
could be involved in controlling the different functions
of these cells. As has already been mentioned, a
potential role for the neuropeptide in controlling TEC
growth is suggested by the inhibitory effect of both SS
and its octapeptide analogue octreotide on unstimulated
and growth factor-stimulated proliferation of cultured
TEC (30). Interestingly, pituitary hormones, which are
under hypothalamic SS control, such as growth
hormone and prolactin, as well as insulin-like growth
factor-I enhance TEC proliferation (41±43). However,
since sst2A is the SST subtype mainly involved in
controlling secretion processes by neuroendocrine
cells, the possibility that this might be valid for thymic
cells as well cannot be ruled out. In fact, TEC and
macrophages produce a signi®cant number of thymic
hormones and cytokines, and these thymic secretory
substances have previously been demonstrated to be
in¯uenced by other neuroendocrine factors (24). Both
TEC and macrophages drive the maturation of thymo-
cytes and are actively implicated in the positive and
negative selection of the future T lymphocytes. The
presence of speci®c SST on these cells suggests the
involvement of the neuropeptide in regulating these
highly specialized cell activities in the thymus. On the
other hand, SS and other neuropeptides have been
reported to effectively modulate proliferation, cytokine
production and antigen presentation by macrophages
in the skin under physiological and pathophysiological
conditions (44).
The pattern of SST subtype expression on thymocytes
seems to follow a predisposed order related to the
different stage of maturation of the lymphoid cells.
Moreover, sst3 is the SST subtype mainly expressed on
thymocytes (D Ferone, PM van Hagen, SWJ Lamberts &
LJ Ho¯and, unpublished observations). Interestingly,
this receptor seems to be selectively expressed on
peripheral resting T lymphocytes, which directly
derive from mature thymocytes (33). In the thymus,
the majority of thymocytes are destined to die as a
consequence of failing selection (45). Since cell death in
the thymus occurs by apoptosis, the expression of the
sst3 on these cells is intriguing. In fact, this SST subtype
may be involved in agonist-mediated apoptosis (46). The
presence of a receptor involved in this sophisticated
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GnRH, gonadotrophin-releasing hormone; GHRH, growth hormone-
releasing hormone; CRH, corticotrophin-releasing hormone; TRH,
thyrotrophin-releasing hormone; ACTH, adrenocorticotrophic hor-
mone; GH, growth hormone; PRL, prolactin; LH, luteinizing
hormone; VIP, vasoactive intestinal peptide; PACAP, pituitary
adenylate cyclase-activating polypeptide; CGRP, calcitonin gene-
related peptide; n.d., not detected.
process suggests a modulatory activity of SS in
thymocyte deletion. However, further studies should
elucidate whether SS might have an inductive or
protective effect on programmed cell death in the
human thymus. Recently, potent inductors of apoptosis
in thymocytes, such as glucocorticoids, have been found
to be implicated in the rescue of thymocytes from
activation-induced cell death (47).
Emerging data are showing adhesion molecules,
extracellular matrix ligands and receptors involved in
driving thymocyte traf®c, in terms of entrance of
precursors, migration within the thymus, as well as
exit of mature cells from the organ. This process seems
to be in¯uenced by neuroendocrine products as well
(48±52). Since SS and other neuropeptides are involved
in regulating the migration of immune cells in other
compartments throughout the human body (53, 54,
55), and considering the peculiar distribution of SST
within the thymus, SS might play a role in the
modulation of this mechanism. This aspect may be
important considering that a disturbance in this process
could favour traf®c of immature or wrongly selected
cells towards peripheral lymphoid organs, enabling the
development of autoimmune diseases.
The recent availability of antibodies speci®c for sst2A
and sst3 receptors made it possible to further investigate
the cellular localization of these receptor subtypes by
immunohistochemistry in human lymphoid tissues (34,
35). In general, sst2A immunoreactivity has been found
mainly located in areas where stromal cells are
prevalent, while sst3 immunoreactivity occurred pre-
ferentially on cells with lymphoid morphology. The sst2A
immunoreactivity, preferentially located in the medulla
of the thymus is in agreement with the binding of the
sst2-preferring ligand, [
125I-Tyr3]-octreotide, detected
by SST autoradiography, and with the expression of
sst2A mRNA in isolated TEC (30, 31).
A ®nal, but not less important, potential activity of SS
within the thymus might be its involvement in the
control of the physiologic involutive process that occurs
in this lymphoid organ with ageing. The human thymus
undergoes involution and decreases its activity in
producing mature T cells. However, recent evidence
points at the maintenance of an `endocrine' activity of
this organ, which might need a differential regulation
during ageing (19). Binding studies with the sst2-
preferring ligand [125I-Tyr3]-octreotide, evaluated in a
large series of human thymuses by SST autoradiography
and ligand binding on tissue homogenates, showed an
inverse correlation between the number of SS-binding
sites and the chronological age of the thymus (56). In
fact, the score at autoradiography, as well as the number
of SST at membrane homogenate binding (Bmax) were
inversely correlated with the thymus age (P < 0.001).
Further studies are required to clarify whether the
decrease of SST in the human thymus during ageing is a
programmed step during involution or whether it is a
consequence of the process in itself (56).
The local production of SS in the human thymus
seems to be extremely relevant since the neuropeptide
might act at different levels, on different thymic cells
and via different receptor subtypes. Within the human
thymus, SS might be considered as a potential
modulator of the homeostasis of various cell compo-
nents as well as a regulator of their specialized
activities. Moreover, SS seems to directly participate
in the main thymic function, namely the maturation of
the human T cell repertoire. The hypothesis of multiple
functions of SS in the thymus is in line with the similar
observation for another well-known neuropeptide, VIP.
In fact, both SS and VIP are produced within this organ
and a strong compartmentalization of their respective
receptors has been shown on human thymic cells (57).
Like SST, the two VIP receptor subtypes display a
distinct distribution in different thymocyte subsets, at
least on murine and rat thymus, con®rming that the
expression of neuropeptide receptors could be differen-
tially regulated during development (58). Finally, VIP
may also affect multiple aspects of thymic cell functions
(57, 58). An integrated role for these two neuropep-
tides, possibly together with substance P (SP), has
already been hypothesized (28). However, the exact
parameters regulating a hypothetical intrathymic
circuit between these three substances have not yet
been established. In general, in different pathophysio-
logical conditions SS and VIP seem to `counteract' the
effect of SP on immune cells (58±60). However, in
other situations, SS and VIP may have opposite effects
on speci®c cell subsets, while acting synergistically on
others (61).
The hypothesis on the relevance of SS and SST in
thymus physiology discussed above form the basis for a
better understanding of some mechanisms which may
occur in pathological conditions of this organ.
Distribution and signi®cance of SS and SST in
human thymic tumours
Human thymoma is the most common tumour of the
anterio-superior mediastinum and is composed of
cytologically bland, neoplastic TEC accompanied by a
variable admixture of benign lymphocytes (62). This
tumour is frequently associated with paraneoplastic
phenomena, such as myasthenia gravis, and/or other
autoimmune-related disorders and haematological
abnormalities (62). Like other tumours originating
from SS-target tissues, human thymic epithelial
tumours may express SST. These neoplasms have
been visualized in vivo during SST scintigraphy using
[111In-DTPA-d-Phe1]-octreotide (63, 64). Although
ligand-binding studies failed to detect SST on cryostat
sections of human thymomas, at least three SST
subtypes have been detected by immunohistochemistry
using polyclonal antibodies speci®c for sst1, sst2A and
sst3 receptors (28, 65). Moreover, in one case the
expression of SST subtypes was con®rmed at mRNA
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level by RT-PCR analysis (65). Since the number of
receptors in normal thymic tissue as well as in thymoma
is rather low, different sensitivity of the two methods
might, in part, explain this discrepancy. Preliminary
data showed the expression of sst2A and sst3 receptors in
a series of human thymic tumours visualized by in vivo
SST scintigraphy (D Ferone, PM van Hagen, SWJ
Lamberts & LJ Ho¯and, unpublished observations).
Considerable heterogeneity of SST immunoreactivity
was found within and among the tumours. The
heterogeneity of SST expression and the density of
different receptor subtypes might play a crucial role in
determining the in vivo uptake of radiolabelled SS
analogues. Preliminary data suggest that the presence
of sst2 receptors is not an essential prerequisite for the
visualization of SST-positive tissues during [111In-DTPA-
d-Phe1]-octreotide scintigraphy (65). Moreover, sst3
receptors have been shown to display the highest
amount of agonist-dependent receptor internalization
compared with the other SST subtypes (66). Although
the af®nity of octapeptide SS analogues for sst3 is lower
compared with that for sst2, the high internalization of
sst3 receptors might be the possible mechanism
regulating the in vivo uptake of [111In-DTPA-d-Phe1]-
octreotide within thymomas. Indeed, sst3 seems to be
the subtype predominantly expressed in thymomas.
Another suggested hypothesis, which cannot be com-
pletely excluded, is the presence of a novel unidenti®ed
SST involved in determining the in vivo uptake of the
radiotracer.
Receptor turnover and binding properties might be
regulated differently in lymphoid cells compared with
neuroendocrine cells. In fact, the activation of SST
subtypes on lymphoid cells may induce opposite
responses compared with endocrine cells (9, 10, 67).
It has been suggested that thymocytes, which are the
major cell population in the human thymus, can rapidly
down-regulate the expression of their SST when
cultured in vitro (29). Thymocytes are cells with a
wide plasticity in terms of modulation and expression of
surface molecules. From this point of view it would be
interesting to investigate what happens in reactive
thymocytes in thymomas.
In general, in light of these ®ndings it may be
hypothesized that, on the basis of its binding properties
and receptor af®nity, [125I-Tyr3]-octreotide may be
considered as a clear sst2-preferring ligand for in vitro
binding studies. In vivo, several exogenous factors may
in¯uence these properties, playing a role in determining
the uptake of [111In-DTPA-d-Phe1]-octreotide within
SST-expressing tissues and tumours as well. This is a
point that may have important consequences for future
applications of the currently available SS analogue for
systemic radiotherapy, as well as for the development
and use of novel subtype-selective analogues and
antagonists. Data in the literature point to a certain
ef®cacy of treatment with SS analogues in neoplastic
diseases involving organs of the immune system and in
autoimmune diseases (9, 10). Of particular interest is
the reported successful treatment of patients bearing
thymomas associated with paraneoplastic syndromes
with the SS analogue octreotide or with the combina-
tion of octreotide and corticosteroids (64, 68). As far as
the effect on the autoimmune disease is concerned,
further studies should investigate whether the effect of
therapy with SS analogues may have a rationale in the
treatment of the severe autoimmune diseases, which are
frequently associated with thymic disturbances.
The heterogeneity of SST expression pattern in thymic
tumours and the reported effects on the tumour mass
exerted by therapy with SS analogues might represent
another stimulating ®eld for future investigations. In
fact, in one paradigmatic case displaying a signi®cant in
vivo uptake of [111In-DTPA-d-Phe1]-octreotide and a
preferential expression of sst3 receptor, a signi®cant
inhibition of cell proliferation by SS and octreotide has
been shown in vitro (65). SS is endogenously produced
in the normal thymus, suggesting a role of the
neuroeptide in controlling cell homeostasis in this
organ. Conversely, in this thymoma SS mRNA was
undetectable (65). Although very speculative, the loss of
SS in a tumour arising from this organ might be
involved in the pathogenesis of the neoplastic transfor-
mation as well as in the pathogenesis of the associated
autoimmune diseases. However, as previously under-
lined, thymomas represent a highly heterogeneous class
of tumours and further investigations are mandatory to
elucidate the signi®cance of SS and speci®c SST subtype
expression in this class of tumours.
Conclusions
SST on target cells can be actively up- or down-
regulated by exposure to several heterologous agents,
as well as to its own ligand. In general, changes in the
density, quality and activity of local regulatory factors
might alter the distribution and concentration of
neuropeptide receptors and their ligands. This may
also apply to the human thymus, where the global
activity of the organ is based on the balance of several
regulating factors produced locally.
We can conclude that SS and a set of SST are
expressed in the human thymus in both microenviron-
mental and lymphoid cells in an apparently selective
manner. A highly specialized intrathymic circuit seems
to integrate SS in the main function of this organ as well
as in other activities, which needs further investigation.
The age-related involution of this lymphoid organ and
the occurrence of thymic tumour-related autoimmune
diseases are two of the main aspects in which SS and
SST might be involved. However, this points out the
important role of the neuropeptide and its receptors in
thymic homeostasis. The overall activity of the thymus
is based on the balance of several regulating factors,
which can be locally produced. Disturbances in this
delicate equilibrium may lead to the induction of
S32 D Ferone and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2000) 143 SUPPL 1
www.eje.org
unbalanced immune responses. Since alterations in the
circuit involving SS might be implicated in the
pathogenesis of these diseases, therapy with SS analo-
gues might have an application in speci®c thymus-
related immune disorders.
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